Sentinel Lymph Node Biopsy in Pelvic Tumors: Clinical Indications and Protocols Under Investigation

Marco Maccauro, Alice Lorenzoni, Flavio Crippa, Gianpiero Manca, Sotirios Chondrogiannis, Francesco Giammarile, Patrick M. Colletti, Gary J. Cook, Domenico Rubello

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Sentinel lymph node (SLN) sampling is an attractive alternative to complete lymphadenectomy. Based on the identification and sampling of the first LN draining a primary tumor, SLN biopsy is the most accurate and the only reliable method for microscopic nodal staging for solid tumors including breast cancer and melanoma. Lymph node status in pelvic tumors remains the most important prognostic factor for recurrence and survival and a major decision criterion for adjuvant therapy. We review the clinical indications, controversies, and perspective of SLN biopsy in male and female pelvic cancers.

Original languageEnglish
JournalClinical Nuclear Medicine
DOIs
Publication statusAccepted/In press - Feb 24 2016

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Sentinel Lymph Node Biopsy in Pelvic Tumors: Clinical Indications and Protocols Under Investigation'. Together they form a unique fingerprint.

  • Cite this

    Maccauro, M., Lorenzoni, A., Crippa, F., Manca, G., Chondrogiannis, S., Giammarile, F., Colletti, P. M., Cook, G. J., & Rubello, D. (Accepted/In press). Sentinel Lymph Node Biopsy in Pelvic Tumors: Clinical Indications and Protocols Under Investigation. Clinical Nuclear Medicine. https://doi.org/10.1097/RLU.0000000000001184